Sarepta Therapeutics (NASDAQ:SRPT) : The total money flow in Sarepta Therapeutics (NASDAQ:SRPT) was negative ($1.45 million), showing the domination of sellers in the Wednesday trading session. The traders utilized every rise to sell their positions, as seen in the value of trading on downtick to the tune of $3.7 million. Transactions on upticks were comparatively lower at $2.24 million. The uptick to downtick ratio was 0.61. The total block trades done on upticks were valued at $0.29 million. The total block trades on downticks were valued at $0 million. The money flow during block trades was negative ($0.29 million) when the stock traded with a gain of $14 cent. Sarepta Therapeutics (NASDAQ:SRPT) was $17.95, an increase of 0.79% over the previous days close.
In an insider trading activity, Behrens M Kathleen, director of Sarepta Therapeutics, Inc., executed a transaction worth $1,165,500 on March 14, 2016. A total of 75,000 shares were purchased at an average price of $15.54. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered. Currently the company Insiders own 10.9% of Sarepta Therapeutics shares according to the proxy statements. Institutional Investors own 73.34% of Sarepta Therapeutics shares. During last six month period, the net percent change held by insiders has seen a change of 4.44%.
The company shares have dropped -40.13% from its 1 Year high price. On Oct 5, 2015, the shares registered one year high at $41.97 and the one year low was seen on Apr 26, 2016. The 50-Day Moving Average price is $18.44 and the 200 Day Moving Average price is recorded at $19.84. Sarepta Therapeutics (NASDAQ:SRPT): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $17.88 and $17.64 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $18.74. The buying momentum continued till the end and the stock did not give up its gains. It closed at $18.66, notching a gain of 4.77% for the day. The total traded volume was 3,341,061 . The stock had closed at $17.81 on the previous day.
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.